salmeterol xinafoate has been researched along with Muscle Contraction in 3 studies
salmeterol : A racemate consisting of equal parts of (R)- and (S)-salmeterol. It is a potent and selective beta2-adrenoceptor agonist (EC50 = 5.3 nM). Unlike other beta2 agonists, it binds to the exo-site domain of beta2 receptors, producing a slow onset of action and prolonged activation.
2-(hydroxymethyl)-4-(1-hydroxy-2-{[6-(4-phenylbutoxy)hexyl]amino}ethyl)phenol : A phenol having a hydroxymethyl group at C-2 and a 1-hydroxy-2-{[6-(4-phenylbutoxy)hexyl]amino}ethyl group at C-4; derivative of phenylethanolamine.
Muscle Contraction: A process leading to shortening and/or development of tension in muscle tissue. Muscle contraction occurs by a sliding filament mechanism whereby actin filaments slide inward among the myosin filaments.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Furthermore, 29b was found to have low oral bioavailability in rat and dog and also to have long duration of action in an in vivo model of bronchodilation." | 1.35 | Synthesis and structure-activity relationships of long-acting beta2 adrenergic receptor agonists incorporating arylsulfonamide groups. ( Barrett, VJ; Bevan, NJ; Biggadike, K; Butchers, PR; Coe, DM; Conroy, R; Edney, DD; Field, RN; Ford, AJ; Guntrip, SB; Looker, BE; McLay, IM; Monteith, MJ; Morrison, VS; Mutch, PJ; Procopiou, PA; Richards, SA; Sasse, R; Smith, CE, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Alikhani, V | 1 |
| Beer, D | 1 |
| Bentley, D | 1 |
| Bruce, I | 1 |
| Cuenoud, BM | 1 |
| Fairhurst, RA | 1 |
| Gedeck, P | 1 |
| Haberthuer, S | 1 |
| Hayden, C | 1 |
| Janus, D | 1 |
| Jordan, L | 1 |
| Lewis, C | 1 |
| Smithies, K | 1 |
| Wissler, E | 1 |
| Procopiou, PA | 1 |
| Barrett, VJ | 1 |
| Bevan, NJ | 1 |
| Biggadike, K | 1 |
| Butchers, PR | 1 |
| Coe, DM | 1 |
| Conroy, R | 1 |
| Edney, DD | 1 |
| Field, RN | 1 |
| Ford, AJ | 1 |
| Guntrip, SB | 1 |
| Looker, BE | 1 |
| McLay, IM | 1 |
| Monteith, MJ | 1 |
| Morrison, VS | 1 |
| Mutch, PJ | 1 |
| Richards, SA | 1 |
| Sasse, R | 1 |
| Smith, CE | 1 |
| Xing, G | 1 |
| Woo, AY | 1 |
| Pan, L | 1 |
| Lin, B | 1 |
| Cheng, MS | 1 |
1 review available for salmeterol xinafoate and Muscle Contraction
| Article | Year |
|---|---|
Recent Advances in β
Topics: Adrenergic beta-2 Receptor Agonists; Asthma; Clinical Trials as Topic; Heart Failure; Humans; Muscle | 2020 |
2 other studies available for salmeterol xinafoate and Muscle Contraction
| Article | Year |
|---|---|
Long-chain formoterol analogues: an investigation into the effect of increasing amino-substituent chain length on the beta2-adrenoceptor activity.
Topics: Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Albuterol; Animals; Ethanolamines; Fo | 2004 |
Synthesis and structure-activity relationships of long-acting beta2 adrenergic receptor agonists incorporating arylsulfonamide groups.
Topics: 2-Hydroxyphenethylamine; Administration, Oral; Adrenergic beta-2 Receptor Agonists; Albuterol; Anima | 2009 |